RI/MOM

RI/MOM
Name	RI/MOM
Specialty	Nuclear medicine; diagnostic imaging

RI/MOM

RI/MOM is a nuclear medicine technique combining radiotracer distribution assessment with mathematical modeling to quantify regional physiology. It integrates concepts from diagnostic imaging, pharmacokinetics, and signal processing to infer tissue function from time‑activity data. Developed through collaboration among hospitals, research institutes, and industry, RI/MOM has applications in cardiology, oncology, neurology, and renal medicine.

Definition and Overview

RI/MOM is defined as a radiotracer‑based imaging and modeling framework that extracts physiologic parameters from dynamic scanning data. The technique uses radiopharmaceuticals, detectors, and compartmental or noncompartmental models to derive metrics such as perfusion, metabolism, and receptor binding. RI/MOM interfaces with modalities and institutions historically associated with diagnostic innovation, including Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Cleveland Clinic, Karolinska Institute, Memorial Sloan Kettering Cancer Center, University College London, Imperial College London, Stanford University Medical Center, Harvard Medical School, University of Oxford, University of Cambridge, National Institutes of Health, Mount Sinai Hospital, University of California, San Francisco, Duke University Hospital, Yale New Haven Hospital, Columbia University Irving Medical Center, University of Pennsylvania Health System, King's College London, University of Toronto, McGill University Health Centre, Vanderbilt University Medical Center, Northwestern Memorial Hospital, University of Michigan Hospitals and Health Centers, University of Chicago Medicine, Thomas Jefferson University Hospital, Brown University, Princeton University, California Institute of Technology, ETH Zurich, University of Tokyo, Osaka University, Seoul National University Hospital, Peking University Health Science Center, Peter MacCallum Cancer Centre, Royal Prince Alfred Hospital, Hospital Clínic de Barcelona, Karlsruhe Institute of Technology, Paul Scherrer Institute, and Paul Ehrlich Institute.

History and Development

Origins trace to early radiotracer work and quantitative physiology studies at institutions linked to pioneers such as George de Hevesy, Ernest Lawrence, Glenn Seaborg, John Lawrence, Allan Cormack, Godfrey Hounsfield, William H. Bragg, and laboratories associated with Los Alamos National Laboratory, Brookhaven National Laboratory, Oak Ridge National Laboratory, Lawrence Berkeley National Laboratory, Argonne National Laboratory, CERN, and National Physical Laboratory (United Kingdom). Key clinical translation milestones occurred alongside development of radionuclides like Technetium‑99m, Fluorine‑18, Iodine‑123, Gallium‑68, and Carbon‑11 and imaging hardware advances from vendors such as GE Healthcare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems, Hitachi Medical Corporation, Toshiba Corporation, and Shimadzu Corporation. Methodological advances drew on mathematical work by figures connected to Andrey Kolmogorov, Richard Bellman, Alan Turing, Norbert Wiener, and statistical frameworks from Karl Pearson and Ronald Fisher; clinical uptake followed guidelines from bodies like World Health Organization, International Atomic Energy Agency, European Medicines Agency, U.S. Food and Drug Administration, National Institute for Health and Care Excellence, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, European Association of Nuclear Medicine, American Heart Association, American Society of Clinical Oncology, and national health services.

Technical Principles and Methodology

RI/MOM relies on dynamic acquisition of radiotracer time‑activity curves using gamma cameras, single‑photon emission computed tomography, or positron emission tomography scanners. Core methodology uses compartmental modeling, kinetic rate constants, deconvolution, spectral analysis, parametric imaging, and model selection techniques informed by work in numerical analysis and signal processing associated with John von Neumann, Claude Shannon, Steven G. Krantz, Gene H. Golub, and algorithms from groups at Bell Labs, MIT Lincoln Laboratory, Los Alamos National Laboratory, and IBM Research. Data correction uses attenuation coefficients from Hans Christian Ørsted‑era physics and scatter models consistent with standards endorsed by International Commission on Radiological Protection, International Electrotechnical Commission, and Institute of Electrical and Electronics Engineers. Implementation integrates tracer kinetic models originally applied in studies by researchers at University of California, Los Angeles, University of Cambridge, Imperial College London, Karolinska Institute, and Massachusetts General Hospital.

Clinical Applications and Indications

RI/MOM is applied to quantify myocardial blood flow, cerebral metabolism, tumor perfusion, renal plasma flow, and receptor occupancy for therapeutic monitoring. Clinical scenarios involve collaboration with specialties and centers such as American College of Cardiology, European Society of Cardiology, National Cancer Institute, European Society for Medical Oncology, American Society of Nephrology, American Academy of Neurology, International Society for Magnetic Resonance in Medicine, Society of Nuclear Medicine and Molecular Imaging, and multidisciplinary teams from hospitals like Massachusetts General Hospital, Johns Hopkins Hospital, Memorial Sloan Kettering Cancer Center, Mayo Clinic, and UCLA Medical Center.

Safety, Risks, and Contraindications

Safety assessment follows radiobiology and radiation protection frameworks developed by Hermann Joseph Muller, Marie Curie, Irène Joliot‑Curie, and agencies such as International Atomic Energy Agency, World Health Organization, U.S. Nuclear Regulatory Commission, European Commission, and Food and Drug Administration. Contraindications and risk management overlap with protocols from American College of Radiology and institutional review boards at academic centers like Harvard Medical School, Stanford University, Yale School of Medicine, and Johns Hopkins University School of Medicine.

Interpretation and Reporting

Interpretation integrates quantitative outputs with clinical context provided by referring services including American College of Radiology, Royal College of Radiologists, European Association of Nuclear Medicine, Society of Nuclear Medicine and Molecular Imaging, and specialty societies in cardiology, oncology, and neurology. Reporting templates and standardized terminology align with initiatives from Radiological Society of North America, American College of Radiology, STARD, CONSORT, and regulatory guidance from U.S. Food and Drug Administration and European Medicines Agency.

Regulatory and Ethical Considerations

Regulation of RI/MOM involves approvals and oversight by bodies such as U.S. Food and Drug Administration, European Medicines Agency, International Atomic Energy Agency, U.S. Nuclear Regulatory Commission, Medicines and Healthcare products Regulatory Agency, Health Canada, Therapeutic Goods Administration (Australia), and ethics review by institutional review boards at NIH Clinical Center, Mayo Clinic, Massachusetts General Hospital, Johns Hopkins Hospital, and international academic centers. Ethical frameworks draw on principles articulated in documents associated with Nuremberg Code, Declaration of Helsinki, Belmont Report, and professional codes from World Medical Association.

Category:Nuclear medicine